The forum, positioned at the beginning of JPM week, focuses on the latest developments across key areas of Neuroscience which are currently drawing widespread investor interest. The program features 8+ hours of keynotes and panel discussions addressing the important advances in therapeutic, neurotech and diagnostics fields.
Lumanity will be chairing a panel:
The Future of Psychedelics
Co-Chaired by:
– Ginger Johnson, President, BioConsulting, Lumanity
– Sumant Kulkarni, Managing Director, Biotechnology Equity Research, CanaccordGenuity LLC
Panelists:
– Doug Drysdale, CEO, Cybin Inc.
– Greg Mayes, President & CEO, Reunion Neuroscience, Inc.
– Joseph Tucker, CEO, Enveric BioSciences, Inc.
– Kabir Nath, CEO, Compass Pathways
– Robert Barrow, CEO, MindMed
– Sahil Kirpekar, CBO, atai Life Sciences N.V.
Connect with our staff or schedule a time to meet during the meeting by reaching out to contact@lumanity.com.